PGV 002
Alternative Names: Personalized neoantigen tumor vaccine - NeoCura; PGV-002; PGV002 mRNA vaccineLatest Information Update: 23 Jun 2023
At a glance
- Originator NeoCura
- Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Solid tumours
Most Recent Events
- 03 May 2022 NeoCura and Peking Union Medical College Hospital plans a clinical trial in Solid tumours (Monotherapy, Combination therapy, In adults, In the elderly, Second-line therapy or greater, Late stage disease) in June 2022 (NCT05359354)
- 28 Feb 2022 Clinical trials in Solid tumours (Late-stage disease, In adults, In the elderly, Second-line therapy or greater, Combination therapy) in China (Parenteral) (NCT05192460)
- 28 Feb 2022 Clinical trials in Solid tumours (Late-stage disease, In adults, In the elderly, Second-line therapy or greater, Monotherapy) in China (Parenteral) (NCT05192460)